The latest price target for Exagen (NASDAQ:XGN) was reported by Canaccord Genuity on March 11, 2026. The analyst firm set a price target for $10.00 expecting XGN to rise to within 12 months (a possible 224.68% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Exagen (NASDAQ:XGN) was provided by Canaccord Genuity, and Exagen maintained their buy rating.

The last upgrade for Exagen Inc happened on July 30, 2025 when Keybanc raised their price target to $12. Keybanc previously had a sector weight for Exagen Inc.

There is no last downgrade for Exagen.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exagen was filed on March 11, 2026 so you should expect the next rating to be made available sometime around March 11, 2027.

While ratings are subjective and will change, the latest Exagen (XGN) rating was a maintained with a price target of $15.00 to $10.00. The current price Exagen (XGN) is trading at is $3.08, which is out of the analyst’s predicted range.